10 minute read
May 11, 2023

ACT-777991: Next-Generation CXCR3 Antagonist in Phase I Trials for Type 1 Diabetes

ACT-777991

oral reversible CXCR3 antagonist Ph. I in healthy subjects opt. of known CXCR3 antagonists J. Med. Chem., March 8, 2023 Idorsia Pharmaceuticals Ltd, CH

drughunter.com
Drug Hunter Team

ACT-777991, an oral and insurmountable CXCR3 antagonist discovered by Idorsia (formerly Actelion), is under investigation for the treatment of Type 1 Diabetes (T1D). Despite the complex history of CXCR3 antagonists, ACT-777991 has shown promise with [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in